Paysign (PAYS) Q1 2026 earnings review
Operating Leverage Shines as Pharma Engine Accelerates
Paysign delivered an exceptionally strong Q1, pushing revenue up 51% YoY to $28.0M and effortlessly translating that top-line beat into bottom-line outperformance. The company is experiencing a profound operating leverage inflection: while revenue grew 51%, operating expenses rose only 25.5%, allowing operating margins to rapidly expand from 13.4% to 23.8%. The Pharma Patient Affordability segment remains the undisputed growth driver (+82% YoY), but importantly, the legacy Plasma business also rebounded with 25% growth. While management reiterated an optimistic full-year forecast, the Q2 guidance indicates standard sequential deceleration due to Pharma's Q1 seasonal peak, and rising center attrition to competitors in the Plasma segment warrants close monitoring.
🐂 Bull Case
Paysign's fixed-cost platform is scaling beautifully. With Gross Margins reaching 65.0% and SG&A growth lagging revenue growth by over 30 percentage points, the resulting margin expansion nearly doubled net income.
The legacy plasma segment showed reversing momentum, jumping 24.9% YoY. Management cited the first increase in loads per center since the 2024 industry-wide inventory correction, signaling returning end-market demand.
🐻 Bear Case
Despite segment revenue growth, Paysign lost 20 underperforming plasma centers to a direct competitor, causing total active centers to decline sequentially from 595 to 573. Retaining footprint scale remains a risk.
Pharma revenue is highly seasonal and peaks in Q1 due to patient affordability claims resets. The resulting sequential deceleration guided for Q2 requires investors to look strictly at YoY comps rather than sequential momentum.
⚖️ Verdict: 🟢
Bullish. Paysign successfully proved it can scale its top-line Pharma success directly into significant EBITDA and Net Income generation. The return to growth in the Plasma segment provides an unexpected tailwind.
Key Themes
Pharma Affordability Remains the Growth Engine
Accelerating. The Pharma segment continues its dominant trajectory, with Q1 revenue jumping 81.9% YoY to $15.68M. The company successfully added 45 net patient affordability programs over the past twelve months, exiting with 135 active programs. The segment's higher margins are the primary driver pulling total corporate gross margins up to 65.0%.
Plasma Dynamics: Revenue Rebounds Despite Center Losses
Reversing. After multiple quarters of facing severe industry headwinds, the Plasma segment reversed course, posting 24.9% YoY growth to $11.75M. Average monthly revenue per center expanded from $6,517 to $6,671. Crucially, the average number of loads per center grew for the first time since the 2024 industry inventory correction, signaling an end to the destocking macro headwind.
Competitive Attrition in Plasma Centers
While overall plasma revenues look healthy, a look under the hood reveals a concerning data point: total active plasma centers contracted sequentially from 595 at the end of 2025 to 573 in Q1 2026. Management explicitly noted 20 centers were sold to companies utilizing a competing provider. While these centers were underperforming (averaging <$3,500/month), it proves that competitors are actively eroding Paysign's physical market share footprint.
Platform Scalability and Operating Leverage
Accelerating. The operating leverage story is crystallizing flawlessly. While total revenue shot up 50.8%, total operating expenses only grew 25.5%. Even as the company absorbs higher depreciation/amortization (+46.4%) and operating costs from a newly launched customer service center, the fixed-cost nature of the payments and SaaS processing platform allowed Adjusted EBITDA to surge 113.4%.
Rising Support Infrastructure Costs
Stable. Cost of revenues increased by 42.2%, heavily driven by higher call center support expenses. With a new customer service contact center going live in late 2025 to support the Pharma segment's rapid growth, management will need to maintain a careful balance to prevent support costs from cannibalizing gross margins as the affordability program volume scales.
SaaS Platform Broadening Market Appeal
Management specifically highlighted strong reception to its newly rolled-out Software-as-a-Service (SaaS) technology solutions. Not only is this targeting collectors, but specifically plasmapheresis manufacturers, signaling Paysign's shift from a pure payment-processing vendor to an integrated operational tech stack partner across the life sciences ecosystem.
Other KPIs
Accelerating drastically. Up 113.4% YoY from $4.96M. Adjusted EBITDA margin expanded to an impressive 37.8% (up from 26.7% YoY), cementing management's claims regarding platform scalability and fixed-cost leverage.
Stable. Decreased slightly by $523K from year-end 2025. This healthy cash position, completely free of bank debt, allows the company to confidently fund its 2026 CapEx and SaaS software development initiatives internally.
Reversing upward. Spiked from 20.5% in the prior year period. The elevated rate was primarily driven by discrete item adjustments related to the steep increase in stock-based compensation valuation resulting from the company's soaring stock price.
Guidance
Decelerating sequentially. This reflects the standard seasonality in the Pharma segment, where affordability claims typically peak in Q1. However, on a YoY basis, the midpoint implies a robust ~38.7% growth rate, confirming the structural momentum remains intact.
Stable. Reaffirmed guidance implying 30-35% YoY growth. Management expressed high confidence in hitting the upper half of this range based on Q1's comprehensive beat.
Accelerating. Reiterated. Based on $10.59M generated in Q1 alone, achieving this target requires an average of roughly $7.1M per quarter for the remainder of the year, which appears highly achievable given the operating leverage trends.
Accelerating for Pharma, Decelerating for Plasma. Indicates an aggressive pipeline of 12-15 new Pharma program launches expected in Q2 alone. Conversely, guidance implies a continued slow bleed of ~15 additional plasma centers from the Q1 exit count.
Key Questions
Plasma Center Attrition Undercurrents
The sale of 20 centers to competitors is a notable headline. Beyond these being 'underperforming' locations, is there an aggressive competitive pricing cycle emerging, and what steps are being taken to protect the top-tier, high-volume centers?
Pharma Client Mix and Seasonality Curve
As the Pharma segment becomes the dominant revenue source, how has the mix between specialty and retail drugs shifted, and does the Q1 seasonality curve become steeper as total active programs surpass 150?
International SaaS Revenue Monetization
With mentioned reception from European and Asian plasmapheresis manufacturers regarding the new SaaS solutions, when should investors expect these software deployments to generate material, distinct recurring revenue separate from the legacy payment processing models?